Nisoldipine

A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.

Also Known As:

Networked: 356 relevant articles (55 outcomes, 86 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Appel, Daniel: 4 articles (10/2007 - 09/2006)
2.	Benndorf, Ralf A: 4 articles (10/2007 - 09/2006)
3.	Maas, Renke: 4 articles (10/2007 - 09/2006)
4.	Schwedhelm, Edzard: 4 articles (10/2007 - 09/2006)
5.	Böger, Rainer H: 3 articles (10/2007 - 09/2006)
6.	Chen, Hui: 2 articles (02/2010 - 12/2009)
7.	Jiang, Ru: 2 articles (02/2010 - 12/2009)
8.	Silberhorn, Elisabeth: 2 articles (04/2007 - 09/2006)
9.	White, William B: 2 articles (04/2007 - 09/2003)
10.	Schulze, Friedrich: 2 articles (03/2007 - 09/2006)

Related Diseases

1.	Ischemia 08/01/1985 - "The rate-pressure product was significantly greater with nisoldipine than with placebo at the onset of ischemia and at peak exercise (22.8 +/- 1.1 versus 20 +/- 1.4 X 10(3) U for the 20 mg dose; p less than 0.01). " 03/15/1991 - "The results indicate that nisoldipine was effective in improving all exercise parameters and only partially effective in suppressing ischemia during daily activity." 01/01/1989 - "[Protective effects of m-nisoldipine and nisoldipine on myocardial damage in working rabbit hearts after ischemia-reperfusion]." 07/01/1992 - "The improved functional recovery of reperfused myocardium in dogs pretreated with nisoldipine cannot be attributed to an increased regional myocardial blood flow during ischemia or reperfusion. " 06/01/1992 - "The present study was designed to determine the effects of the Ca2+ antagonist nisoldipine on the relationship between [Ca2+]i and left ventricular contraction and relaxation during ischemia and reperfusion on a beat-to-beat basis. "
2.	Stable Angina 11/01/1996 - "The purpose of the study was to evaluate the onset and duration of antianginal and anti-ischemic efficacy of a single oral dose of nisoldipine compared with placebo in patients with stable angina pectoris. " 11/01/1996 - "Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: a randomized, double-blind, placebo-controlled trial." 08/01/1995 - "Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (Coat Core) in chronic stable angina." 06/15/1994 - "Antianginal and anti-ischemic efficacy of immediate-release nisoldipine in chronic stable angina pectoris." 11/01/1996 - "In 33 patients with stable angina pectoris, nisoldipine was tested (10 mg daily) in a randomized, double-blind, placebo-controlled study. "
3.	Hypertension (High Blood Pressure) 01/01/1999 - "Nisoldipine coat-core (nisoldipine CC), an extended-release once-daily formulation, is an effective treatment for mild-to-moderate hypertension, providing sustained blood pressure control over the 24-hour dosing interval. " 09/01/1997 - "Canadian Nisoldipine CC Hypertension Trial Group." 01/01/1997 - "In a third study using ambulatory blood pressure monitoring in black patients with severe hypertension, nisoldipine CC maintained blood pressure control over the 24-hour dosing period. " 04/01/1996 - "Twenty-four patients completed a dose ranging study of the effect of nisoldipine as monotherapy in the treatment of hypertension. " 12/08/2022 - "Nisoldipine, a selective Ca2+ channel inhibitor, is commonly used in the treatment of hypertension. "
4.	Coronary Artery Disease (Coronary Atherosclerosis) 11/01/1989 - "The prolonged efficacy of nisoldipine could be favourable in oral long-term treatment of patients with coronary artery disease." 12/01/1985 - "These data demonstrated improved rest and exercise cardiac performance following nisoldipine in patients with severe coronary artery disease." 08/01/2003 - "The NICOLE study (NIsoldipine in COronary artery disease in LEuven) is a single centre, randomised, double blind, placebo controlled trial with coronary angiography at baseline, six months, and three years of follow up. " 08/01/2003 - "Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study." 08/01/2003 - "Nisoldipine has no demonstrable effect on the angiographic progression of coronary atherosclerosis or the risk of major cardiovascular events but its use is associated with fewer revascularisation procedures."
5.	Left Ventricular Dysfunction 07/01/1996 - "Nisoldipine improved LV diastolic dysfunction and exercise tolerance in patients with HCM. " 04/27/1995 - "Why is nisoldipine a specific agent in ischemic left ventricular dysfunction?" 07/01/1993 - "Nisoldipine in severe ischaemic left ventricular dysfunction." 07/01/1992 - "The aim of this study was to clarify the mechanisms responsible for the increase in early filling rate observed during oral nisoldipine therapy in patients with ischaemic left ventricular (LV) dysfunction. " 07/01/1994 - "Effects of nisoldipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischaemic left ventricular dysfunction."

Related Drugs and Biologics

1.	Calcium
2.	Nifedipine (Adalat)
3.	Calcium Channel Blockers (Blockers, Calcium Channel)
4.	1,4-dihydropyridine (dihydropyridine)
5.	Antihypertensive Agents (Antihypertensives)
6.	Amlodipine (Norvasc)
7.	Nitrendipine
8.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
9.	Enalapril
10.	Verapamil (Calan)

Related Therapies and Procedures

1.	Therapeutics
2.	Microelectrodes
3.	Intravenous Administration
4.	Aftercare (After-Treatment)
5.	Intravenous Injections